Metabolomics Market: Global Industry Analysis and Forecast (2023-2029)

By 2029, the Metabolomics Market is expected to reach 20.16 billion. The Metabolomics instrument is one of the segments studied in the report dominating the Metabolomics market.
Metabolomics Market Overview:
The Metabolomics is the systematic study of chemical processes in cell metabolism that involve metabolites, small molecule substrates, intermediates, and products. Also Metabolomics is the "systematic study of the distinctive chemical fingerprints left behind by specific biological processes," or the study of their small-molecule metabolite profiles. The metabolome refers to the entire range of metabolites produced by cellular processes in a biological cell, tissue, organ, or organism. The set of gene products created in the cell is revealed by messenger RNA (mRNA), gene expression data, and proteomic analysis, data that reflects one element of cellular activity.To know about the Research Methodology :- Request Free Sample Report

Metabolomics is a fast-growing area that combines sophisticated analytical techniques for identifying and quantifying cellular metabolites with statistical and multivariant methods for information extraction and data interpretation. In the recent two decades, tremendous progress has been achieved in the sequencing of a variety of organisms. Simultaneously, significant resources were invested in developing analytical methods for analyzing various cell products, such as gene expression (transcripts), proteins, and metabolites. All of these so-called 'omics methods, such as genomics, transcriptomics, proteomics, and metabolomics, are thought to be crucial tools for understanding an organism's biology and response to environmental stimuli or genetic disruption.
Metabolomics Market Dynamics:
Availability of government and commercial financing for metabolomics research is a driving force.

Metabolomic studies are gaining traction in the life sciences industry since they can show the optimal level of certain metabolites linked to illness onset/progression, as well as treatment exposure and response. With the rising frequency and mortality rates of life-threatening diseases such as cancer and cardiovascular disease (CVD), researchers are focusing more on creative approaches that can provide better diagnosis and therapy.

Additional study is being undertaken on this subject since metabolomics is considered a revolutionary method with significant potential. In addition, metabolomic indicators have become more important in medication development in recent years and this element is projected to lift the growth of the Metabolomic market.

Metabolomics: an evolving but powerful tool for precision medicine

Metabolomics, or the inclusive examination of metabolites in a biological material, is a new technology that has the potential to revolutionize precision medicine. Small quantities of metabolites have traditionally been utilized to detect complex metabolic diseases as well as monogenic disorders such as inborn metabolic abnormalities. Current metabolomic methods are capable of meticulous analysis of hundreds to thousands of metabolites, much exceeding the scope of typical clinical chemistry procedures. As a result, metabolomics enables detailed phenotyping of metabolic phenotypes and can enable precision medicine on a variety of levels, including the identification of metabolic instabilities that reinforce disease, the discovery of new therapeutic targets, and the identification of biomarkers that can be used to diagnose a disease or monitor therapeutic activity. hence, advancement in the field of biomarkers and technologies is likely to lift the growth of the Metabolomics market.
Identifying biomarkers for clinical use: (Challenge)

The delayed development in discovering which metabolites may serve as potentially useful biomarkers is a fundamental restriction of metabolomics as an emerging healthcare technology. The dynamic nature of metabolism, which can be significantly altered by genetic variances and environmental exposures, makes this more difficult. Furthermore, clinical validation by regulatory agencies is essential before a metabolic test may be used in clinical practice to verify whether it is sensitive enough to identify those at risk or affected by a disease and specific enough to a specific disease process. Hence, time-consuming clinical trials and validations processes are likely to create obstacles in the Metabolomics market.
Key Developments-
Agilent and Thermo Fisher extended their collaboration in 2022 to expand Thermo Fisher's analytical systems' compatibility with Agilent's OpenLAb Chromatography Data System.

Hitachi purchased the remaining shares of Hitachi High-Technologies billion in 2022 and renamed it Hitachi High-Technologies. This business will be in charge of developing chipmaking equipment, as well as industrial materials and systems, as well as producing measurement and analytical equipment.
Metabolomics Market Segment Analysis:
The metabolomics instrument segment is supplementing the growth of the Metabolomics Market.

In 2022, the metabolomics instrument category is predicted to command the biggest proportion of the market. The growth of this segment is expected to be fueled by factors such as technological advancements in analytical instruments in terms of miniaturization, automation, and computerization; an increase in the number of research-related activities worldwide in the fields of medicine, nutraceuticals, and metabolomics; and the strengthening of healthcare infrastructure in developing countries for efficient disease diagnosis and treatment. The biomarker discovery segment accounted for the largest share of the metabolomics market

Biomarker discovery- Metabolomics is also used in Biomarker discovery for decision making. A biomarker, for example, is a chemical that is consistently present in illness samples but not in healthy people. Urine, saliva, bile, and seminal fluid samples offer a wealth of highly informative compounds that may be easily studied using metabolomics fingerprinting or profiling for biomarker development. In addition, in 2022, biomarker discovery is predicted to have the principal market share. The use of metabolic biomarkers to determine a patient's pathophysiological health condition is on the rise. Metabolomics has been a critical technique in the discovery of biomarkers in recent years as a result of considerable technological improvements.

The cancer segment is anticipated to adhere to the growth of the Metabolomics Market.

In 2022, the cancer segment is predicted to have the largest market share and the fastest growth rate. This is mostly due to a growth in the number of cancer patients and, as a result, an increase in the demand for cancer medicines. Further, Currently, metabolomics research is being used to find diagnostic cancer biomarkers in the clinic, better comprehend its complicated heterogeneous nature, discover cancer pathways that could be exploited for new targets, and monitor metabolic biomarkers during therapeutic intervention. These metabolomics technologies may also provide information to clinicians regarding a cancer patient's reaction to medical therapies, which could lead to customized cancer treatments.

The academic and research institutes segment is estimated to grab larger market attention in the Metabolomics Market.

The academic and research institutes segment accounted for the largest share of the metabolomics market in 2022. The increasing number of research activities in the field of metabolomics and funding to the academic and research institutes to conduct metabolomics research are the factors responsible for the largest share of the segment
Regional Insights:
North America is dominating the growth of the regional market in the forecast period.

Throughout the projection period, North America is predicted to dominate the worldwide metabolomics market (in terms of market share). High product commercialization rates, as well as advanced healthcare-related research and development projects, are some of the causes contributing to the company's huge market share. In terms of market share, Europe is behind North America. In terms of growth rate, the Asia-Pacific metabolomics market, on the other hand, will outperform both of these areas (CAGR). One of the most significant growth contributors to this market is the rising demand for enhanced pharmaceutical products from emerging economies such as India and China.

The objective of the report is to present a comprehensive analysis of the Metabolomics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Metabolomics Market dynamics, structure by analyzing the market segments and projecting the Metabolomics Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Metabolomics Market make the report investor’s guide.
Metabolomics Market Scope: Inquire before buying



Metabolomics Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2018 to 2022
Market Size in 2022:
US $ 11.09 Bn.


Forecast Period 2023 to 2029 CAGR:
8.9%
Market Size in 2029:
US $ 20.16 Bn.


 Segments Covered:
by Product and Services
Metabolomics Instruments
Separation Tool
Detection Tool
Bioinformatics Tools and Service


by Indication
Cancer
Cardiovascular Disorders
Neurological Disorders
Metabolic Disorders
Inborn Errors of Metabolism
Other Indications


by Application
Biomarker discovery
Drug discovery
Toxicology testing
Nutrigenomics
Functional Genomics
Personalized medicine
Other Applications


by End-User
Academic and Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Other End Users



Metabolomics Market, by Region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Key Players
1. Waters Corporation (US)
2. Agilent Technologies (US)
3. Shimadzu Corporation (Japan)
4. Thermo Fisher Scientific (US)
5. Danaher Corporation (US)
6. Bruker Corporation (US)
7. PerkinElmer (US)
8. Merck KGaA (Germany)
9. GE Healthcare (US)
10. Hitachi High-Technologies Corporation (Japan)
11. Human Metabolome Technologies, Inc. (Japan)
12. LECO Corporation (US)
13. Metabolon, Inc. (US)
14. Bio-Rad Laboatories (US)
15. Scion Instruments (US)
16. DANI Instruments S.p.A. (Italy)
17. GL Sciences (Japan)
18. SRI Instruments (US)
19. Kore Technology Ltd. (UK)
20. JASCO, Inc. (US).
FAQs:
1. What is the Metabolomics market value in 2022?
Ans: The Metabolomics market value in 2022 was estimated as USD 11.09 Billion.

2. Which Application is likely to dominate the Metabolomics market growth?
Ans: Application-wise, the biomarker discovery segment is accounted for the largest market share in 2022. The use of metabolic biomarkers to assess the pathophysiological health status of patients is increasing. In recent years, as a result of significant technological advancements, metabolomics has become a vital tool in discovering biomarkers.

3. Which Region is expected to dominate the Metabolomics market during the forecast period?
Ans: In 2022, North America dominated the Metabolomics market and accounted for the largest revenue share of 51.2%.

4. What are the factors driving the Metabolomics market?
Ans: Key factors that are driving the Metabolomics market growth include rising cancer prevalence, increasing technological advancement, and government funding.

5. Who are the key players in the Metabolomics market?
Ans: The major market players include the metabolomics market is dominated by a few globally established players such as Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific (US), Danaher Corporation (US), Bruker Corporation (US), PerkinElmer (US), Merck KGaA (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan).